Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
CPT: Pharmacometrics & Systems Pharmacology|November 5, 2024
Concentration-QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT intervalJesper Sundell, Dinko Rekic, Johanna Melin, et al.
International Journal of Cancer|February 3, 2005
Oncolysis of human ovarian cancers by echovirus type 1Darren R Shafren, Dianne Sylvester, E Susanne Johansson, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 8, 2015
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activitySusanne Johansson, Willem Talloen, Marianne Tuefferd, et al.
Scandinavian Cardiovascular Journal : SCJ|May 1, 2010
Prediction of drug-related morphological changes of the T waveMicaela Tjäderborn, Maria Aunes-Jansson, Emma Samuelsson, et al.
The Journal of General Virology|March 7, 2009
Molecular characterization of a novel Ljungan virus (Parechovirus; Picornaviridae) reveals a fourth genotype and indicates ancestral recombinationConny Tolf, Maria Gullberg, E Susanne Johansson, et al.
BMJ Sexual & Reproductive Health|October 9, 2024
Home use of mifepristone for medical abortion: a systematic reviewKristina Gemzell-Danielsson, Ingela Lindh, Jan Brynhildsen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|March 17, 2021
A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseasesJacob Leander, Mikael Sunnåker, Dinko Rekić, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 1, 2020
Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized TrialAustin G Stack, Nalina Dronamraju, Joanna Parkinson, et al.
Clinical Pharmacology in Drug Development|March 17, 2017
Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug InteractionsSusanne Johansson, David P Rosenbaum, Marie Ahlqvist, et al.
British Journal of Clinical Pharmacology|April 23, 2017
Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteersSusanne Johansson, David P Rosenbaum, Johan Palm, et al.
Pageof 7